Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients

Abstract Tyrosine kinase inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers including non-small-cell lung cancer (NSCLC). This study aims to evaluate the utility of plasma cell-free DNA (cfDNA) as a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Xiaorong Zhou, Chenchen Li, Zhao Zhang, Daniel Y. Li, Jinwei Du, Ping Ding, Haiyan Meng, Hui Xu, Ronglei Li, Effie Ho, Aiguo Zhang, Paul Okunieff, Jianwei Lu, Michael Y. Sha
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/b2343cf2b10446a4ab9c404bea005c66
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!